These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 20671585)

  • 61. Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment.
    Koh AH; ; Chen LJ; Chen SJ; Chen Y; Giridhar A; Iida T; Kim H; Yuk Yau Lai T; Lee WK; Li X; Han Lim T; Ruamviboonsuk P; Sharma T; Tang S; Yuzawa M
    Retina; 2013 Apr; 33(4):686-716. PubMed ID: 23455233
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Long-term visual outcome and prognostic factors after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy.
    Kang HM; Koh HJ
    Am J Ophthalmol; 2013 Oct; 156(4):652-60. PubMed ID: 23891333
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Photodynamic therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy: a 30-month multicenter study in Hyogo, Japan.
    Honda S; Kurimoto Y; Kagotani Y; Yamamoto H; Takagi H; Uenishi M;
    Jpn J Ophthalmol; 2009 Nov; 53(6):593-597. PubMed ID: 20020237
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Recurrence of polypoidal choroidal vasculopathy after photodynamic therapy.
    Yamashiro K; Tsujikawa A; Nishida A; Mandai M; Kurimoto Y
    Jpn J Ophthalmol; 2008; 52(6):457-462. PubMed ID: 19089566
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Photodynamic therapy of polypoidal choroidal vasculopathy.
    Rogers AH; Greenberg PB; Martidis A; Puliafito CA
    Ophthalmic Surg Lasers Imaging; 2003; 34(1):60-3. PubMed ID: 12570008
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Two-year visual outcomes after photodynamic therapy in age-related macular degeneration patients with or without polypoidal choroidal vasculopathy lesions.
    Tsuchiya D; Yamamoto T; Kawasaki R; Yamashita H
    Retina; 2009; 29(7):960-5. PubMed ID: 19491727
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Structure of polypoidal choroidal vasculopathy studied by colocalization between tomographic and angiographic lesions.
    Kim JH; Kang SW; Kim TH; Kim SJ; Ahn J
    Am J Ophthalmol; 2013 Nov; 156(5):974-980.e2. PubMed ID: 23958701
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Relationship between clinical characteristics of polypoidal choroidal vasculopathy and choroidal vascular hyperpermeability.
    Koizumi H; Yamagishi T; Yamazaki T; Kinoshita S
    Am J Ophthalmol; 2013 Feb; 155(2):305-313.e1. PubMed ID: 23022162
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Polypoidal choroidal vasculopathy masquerading as neovascular age-related macular degeneration refractory to ranibizumab.
    Stangos AN; Gandhi JS; Nair-Sahni J; Heimann H; Pournaras CJ; Harding SP
    Am J Ophthalmol; 2010 Nov; 150(5):666-73. PubMed ID: 20719300
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Photodynamic therapy versus combination therapy in polypoidal choroidal vasculopathy: changes of aqueous vascular endothelial growth factor.
    Lee MY; Lee WK; Baek J; Kwon OW; Lee JH
    Am J Ophthalmol; 2013 Aug; 156(2):343-8. PubMed ID: 23664208
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Two-year results of photodynamic therapy combined with intravitreal anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy.
    Kim M; Kim K; Kim DG; Yu SY; Kwak HW
    Ophthalmologica; 2011; 226(4):205-13. PubMed ID: 21893965
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Efficacy of Photodynamic Therapy for Polypoidal Choroidal Vasculopathy Associated with and without Pachychoroid Phenotypes.
    Hata M; Tagawa M; Oishi A; Kawashima Y; Nakata I; Akagi-Kurashige Y; Yamashiro K; Ooto S; Tamura H; Miyata M; Miyake M; Ueda-Arakawa N; Takahashi A; Tsujikawa A
    Ophthalmol Retina; 2019 Dec; 3(12):1016-1025. PubMed ID: 31606329
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Associations of complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2) genotypes with subtypes of polypoidal choroidal vasculopathy.
    Tanaka K; Nakayama T; Mori R; Sato N; Kawamura A; Mizutani Y; Yuzawa M
    Invest Ophthalmol Vis Sci; 2011 Sep; 52(10):7441-4. PubMed ID: 21896867
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Association of ARMS2/HTRA1 variants with polypoidal choroidal vasculopathy phenotype in a Korean population.
    Park DH; Kim IT
    Jpn J Ophthalmol; 2012 Jan; 56(1):60-7. PubMed ID: 21959923
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The association of age-related maculopathy susceptibility 2 (ARMS2) and complement factor H (CFH) variants with two angiographic subtypes of polypoidal choroidal vasculopathy.
    Miki A; Honda S; Kondo N; Negi A
    Ophthalmic Genet; 2013 Sep; 34(3):146-50. PubMed ID: 23289808
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Long-term prognosis of polypoidal choroidal vasculopathy with a 5-year remission after an initial combination therapy.
    Kikushima W; Sakurada Y; Yoneyama S; Sugiyama A; Matsubara M; Fukuda Y; Kashiwagi K
    Photodiagnosis Photodyn Ther; 2021 Sep; 35():102453. PubMed ID: 34303031
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The association of age-related maculopathy susceptibility 2 polymorphisms with phenotype in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
    Bessho H; Honda S; Kondo N; Negi A
    Mol Vis; 2011 Apr; 17():977-82. PubMed ID: 21541271
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Factors predictive of visual acuity outcomes 1 year after photodynamic therapy in Japanese patients with polypoidal choroidal vasculopathy.
    Hikichi T; Ohtsuka H; Higuchi M; Matsushita T; Ariga H; Kosaka S; Matsushita R; Takami K
    Retina; 2011 May; 31(5):857-65. PubMed ID: 21124252
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Classic choroidal neovascularization developing after photodynamic therapy in eyes with polypoidal choroidal vasculopathy.
    Imasawa M; Sakurada Y; Iijima H
    Jpn J Ophthalmol; 2011 May; 55(3):241-247. PubMed ID: 21559909
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Clinical features of early and late stage polypoidal choroidal vasculopathy characterized by lesion size and disease duration.
    Okubo A; Hirakawa M; Ito M; Sameshima M; Sakamoto T
    Graefes Arch Clin Exp Ophthalmol; 2008 Apr; 246(4):491-9. PubMed ID: 17917739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.